(HP1) Reduce or Eliminate Silencing Activity
Tao Zhao, Tomasz Heyduk, and Joel C. Eissenberg*
Edward A. Doisy Department of Biochemistry
and Molecular Biology
1402 South Grand Blvd.
St. Louis, MO 63104
*corresponding author
Ph: (314)577-8154
FAX: (314)577-8156
Email:
[email protected]
Copyright 2000 by The American Society for Biochemistry and
Molecular Biology, Inc.
JBC Papers in Press. Published on December 19, 2000 as Manuscript
M010098200 by guest on A
pril 15, 2019 http://w
by guest on A pril 15, 2019
http://w w
w .jbc.org/
D ow
nloaded from
HP1 is an essential heterochromatin-associated protein in
Drosophila. HP1 has dosage-dependent
effects on the silencing of euchromatic genes that are mislocalized
to heterochromatin, and is
required for the normal expression of at least two heterochromatic
genes. HP1 is multiply
phosphorylated in vivo, and HP1 hyperphosphorylation is correlated
with heterochromatin
assembly during development. The purpose of this study was to test
whether HP1
phosphorylation modifies biological activity and biochemical
properties of HP1. To determine
sites of HP1 phosphorylation in vivo and whether phosphorylation
affects any biochemical
properties of HP1, we expressed Drosophila HP1 in lepidopteran
cultured cells using a
recombinant baculovirus vector. Phosphopeptides were identified by
MALDI-TOF mass
spectroscopy; these peptides contain target sites for casein kinase
II, protein tyrosine kinase and
PIM-1 kinase. Purified HP1 from bacterial (unphosphorylated) and
lepidopteran
(phosphorylated) cells has similar secondary structure.
Phosphorylation has no effect on HP1
self-association, but alters the DNA binding properties of HP1,
suggesting that phosphorylation
could differentially regulate HP1-dependent interactions.
Serine-to-alanine and serine-to-
glutamate substitutions at consensus protein kinase motifs resulted
in reduction or loss of
silencing activity of mutant HP1 in transgenic flies. These results
suggest that dynamic
phosphorylation/ dephosphorylation regulates HP1 activity in
heterochromatic silencing.
by guest on A pril 15, 2019
http://w w
w .jbc.org/
D ow
nloaded from
melanogaster (1,2) and a context-dependent regulator of
transcription. HP1 has dosage-
dependent effects on the silencing of euchromatic genes (3-5), and
it is required for the proper
expression of certain heterochromatic genes (6). HP1 is essential
in Drosophila (5); mutations
cause recessive late larval lethality, associated with
misregulation of essential heterochromatic
genes and mitotic defects (6-8). HP1-like proteins have been
identified in yeast, nematodes,
insects, amphibians, and mammals (reviewed in Ref. 9). HP1 family
proteins in S. pombe and
mouse have also been shown to participate in position-dependent
silencing (10,11).
HP1 contains two copies of a structural motif called the chromo
domain, connected by a short
“hinge domain”. The chromo domain structure consists of three
ß-strands packed against an
alpha helix (12,13), a motif found in an archeal DNA-binding
protein (14,15). The C-terminal
chromo domain self-associates in vitro (16). HP1 binds DNA and
nucleosomes in vitro (17).
Heterotypic interactions between HP1 family proteins and silencing
factors (18-22), nuclear
membrane proteins (23,24), and replication factors (25,26) have
also been reported, suggesting
that HP1 family proteins may participate in multiple distinct
nucleoprotein complexes in vivo.
HP1 is multiply phosphorylated by serine-threonine kinases in
Drosophila (27).
Hyperphosphorylation of HP1 correlates with heterochromatin
assembly during development. In
Tetrahymena, the HP1 family protein Hhp1p becomes
hyperphosphorylated in response to
starvation; this is associated with reduction in macronuclear
volume and increased chromatin
condensation (28). Human HP1-family proteins are phosphorylated in
vivo (29), and have been
shown to be substrates in vitro for multiple kinases (21,30).
by guest on A pril 15, 2019
http://w w
w .jbc.org/
D ow
nloaded from
Huang et al. (31) recovered differentially phosphorylated HP1 in
distinct protein complexes from
Drosophila embryo extracts, suggesting that phosphorylation could
regulate the assembly of HP1
into higher order chromatin structures. This study also found a
correlation between the extent of
HP1 phosphorylation and salt extractability from embryo nuclei.
These findings suggest that
HP1 phosphorylation regulates distinct macromolecular interactions
in vivo.
Consensus kinase target sites are found near the N- and C-terminal
ends of Drosophila HP1, and
in the hinge domain between the chromo domain motifs. We recently
reported that casein kinase
II (CKII) from embryo nuclear extract phosphorylates HP1 at three
target sites in vitro, and that
alanine substitutions for CKII target serines interfere with
efficient heterochromatin targeting in
a transient expression assay (32). Our study did not test the
transcriptional regulatory activity of
mutant HP1 proteins.
In this report, we compare the biochemical properties of
phosphorylated and unphosphorylated
HP1. We map sites of phosphorylation in HP1 by expressing
Drosophila HP1 in lepidopteran
cells using a recombinant baculovirus. MALDI-TOF mass analysis of
proteolytic cleavage
products identified products consistent with phosphorylation at
consensus casein kinase II sites
and a protein tyrosine kinase consensus, as well as a
phosphopeptide containing a putative PIM-1
kinase target site. We find that phosphorylation leads to no
significant change in HP1 secondary
structure or self-association, but inhibits HP1 binding to DNA in
vitro. Amino acid substitutions
in consensus phosphorylation sites reduced or eliminated silencing
activity in transgenic flies,
implicating phosphorylation in the regulation of HP1 in vivo.
by guest on A pril 15, 2019
http://w w
w .jbc.org/
D ow
nloaded from
EXPERIMENTAL PROCEDURES
Expression and purification of recombinant HP1—HP1 was expressed in
E. coli and purified as
described previously (32). The BacPAK™ Baculovirus Expression
system (Clontech) was used
to express HP1 in Sf21 cells. An XbaI-KpnI fragment with HP1 cDNA
was inserted into the
pBacPAK8 vector, and infections were performed according to
manufacturers instructions. Cells
were grown at room temperature. After five days of infection, the
cells were harvested, and HP1
expression verified by western blot analysis. For both the
bacterially expressed and baculovirus
expressed proteins, the glycine residue that is normally Gly2 in
HP1 is preceded by the amino
acid sequence MARVDL in both recombinant proteins.
To purify HP1 from the infected cells, ten 75 cm2 flasks of cells
or 500 ml suspension cell
culture was infected with passage two virus. After five days, the
cells were collected by
centrifugation at 1000 x g for 5 min. The cell pellet was lysed in
a buffer of 20 mM HEPES, pH
7.4 / 0.1 M NaCl / 5 mM EDTA / 1 mM DTT / 1 mM PMSF / 1 mM NaF /
0.1 M Na3VO4 / 0.1
% Triton X-100, by sonication on ice. The lysate was centrifuged at
18,000 rpm in an SS34 rotor
(Sorvall) for 30 min, and the supernatant liquid applied to a 1 ml
DEAE column. Proteins were
eluted with 0.5 M NaCl in lysis buffer from the column, and diluted
to 0.1 M NaCl in the same
buffer. The sample was then loaded onto a 1 ml Mono Q column on a
Smart System HPLC
(Pharmacia). The column was developed with a 0.1-0.5 M NaCl
gradient, with HP1 eluting in a
single peak at about 0.4 M NaCl. 2D gel electrophoresis was done as
described (27).
by guest on A pril 15, 2019
http://w w
w .jbc.org/
D ow
nloaded from
Phosphatase treatment of baculovirus-expressed HP1 was performed as
described (27). Briefly, 2
µg potato acid phosphatase (0.8 U/mg; Sigma) was added to a 20 µl
solution of 50 mM Tris-
HCl, pH 6.5 containing 2 µg baculovirus-expressed HP1, and the
mixture was incubated at room
temperature for 15 min. 4 µl of 10 X shrimp alkaline phosphatase
buffer (200 mM Tris-HCl, pH
8.0 / 10 mM MgCl) and 1 µl shrimp alkaline phosphatase (Amersham; 1
U/µl) was added to the
reaction and the volume was brought to 40 µl with distilled water.
After 15 min. incubation at
room temperature, the sample was stored at –70°C until use.
Circular dichroism—CD spectra were recorded using AVIV 60DS CD
spectrophotometer. Five
spectra were collected every 0.5 nm at room temperature for each
sample. The spectra were then
averaged and corrected for the buffer.
DNA binding and cross-linking assays—Purified HP1 (10 µM) was mixed
with 1 mM
disuccinimidyl suberate (Pierce) in the presence of 0.2 M NaCl and
0.05% BSA, and was
incubated on ice for 15 min. The reaction was stopped by adding
SDS-PAGE sample buffer and
boiling for 5 min. After electrophoresis, the proteins were
transferred to nitrocellulose membrane
(Millipore) using a Mini-TransBlot electrophoretic transfer cell
(Bio-Rad) according to
manufacturers instructions. After transfer, the membrane was
blocked with 1% bovine serum
albumin (Fraction V; Sigma) in TBST buffer (10 mM Tris-HCl, pH
8.0/150 mM NaCl/ 0.05%
Tween 20) at room temperature for 30 min. The rabbit anti-HP1 serum
was a gift of Dr. S.C.R.
Elgin (Washington U.), and was used at a 1:10,000 dilution in TBST
buffer. The secondary
antibody was an anti-rabbit IgG-alkaline phosphatase conjugate
(Promega),and was used at a
1:7500 dilution in TBST buffer. Detection was with
5-bromo-4-chloro-3-indoyl phosphate and
by guest on A pril 15, 2019
http://w w
w .jbc.org/
D ow
nloaded from
nitro blue tetrazolium (Promega) as described (33). DNA binding
assay was performed as
described (17), using a 146 bp sea urchin 5S rDNA end-labeled with
the fluorescent dye Cy5.
Proteolytic digestions of HP1 for mass spectroscopy—Two methods
were used to prepare
peptides for MALDI-TOF mass spectroscopy. One method involved
solution digestion by one of
three enzymes. (i) Trypsin of Glu-C: 5 µg of HP1 was mixed with
0.25 µg or trypsin (Sigma) or
Glu-C (Sigma) in a 20µl buffer of 25 mM NH4HCO3, pH 8.0. The
mixture was incubated at 37°C
overnight. (ii) Lys-C: 5 µg of HP1 was mixed with 0.25 of Lys-C
(Sigma) in 20 µl of 25 mM
Tris-HCl, pH 7.7 / 1 mM EDTA. The mixture was incubated at 37°C for
24 h. After digestion,
the peptides were purified and desalted by C18 reverse phase
chromatography (ZipTip;
Millipore), dried in a vacuum, and subject to mass spectroscopy.
The second method for peptide
preparation was to subject intact HP1 to SDS-PAGE, transfer the
protein to PVDF membrane
electrophoretically, localize transferred protein by transient
staining with 0.5% Ponceau S for 30
sec., wash briefly with water, and excise the region of membrane
containing protein. The
membrane fragment was further sliced into small pieces, washed in
water until free of stain, and
incubated in 200 µl of 0.1% polyvinylpyrrolidone 40 (Sigma) in
methanol for 30 min. The
blocked membrane was then incubated in 200 µl water at 37°C for 30
min, rinsed three more
times in water, and submerged in ~20µl of protease in appropriate
buffer for overnight digestion
at 37°C overnight to achieve extensive digestion, or for 1-2 h at
room temperature to yield a
higher fraction of partial digestion products. Following digestion,
the sample was vortexed
briefly and the supernatant liquid was recovered. The membrane
fragments were washed once in
20 µl water or 10% acetonitrile, and this supernatant was combined
with the first for mass
spectroscopy.
http://w w
w .jbc.org/
D ow
nloaded from
MALDI-TOF analysis—All MALDI spectra were obtained using a Voyager
Biospectrometry
Workstation (PerSeptive Biosystems Inc., Framingham MA) in positive
ion linear mode. Three
matricies were used: sinapinic acid was used for intact HP1
analysis, and α-cyano-4-
hydroxycinnaminic acid (CHCA) and 2.5-dihydroxybenzoic acid (DHB)
were used for peptides.
10 mg/ml sinapinic acid or CHCA was dissolved in 50% acetonitrile /
0.3% trifluoroacetic acid.
25 mg/ml DHB was dissolved in 0.6% trifluoroacetic acid / 33%
acetonitrile. Typically, 0.1-5
pmol protein or peptide was dried and resuspended in 2.5-10 µl of
matrix, then 1-2 µl was
immediately spotted on the sample plate. Spectra were obtained from
different regions of the
dried sample, and representative spectra were selected for further
analysis. Time-to-mass
conversion was achieved by internal calibration using angiotensin
II (Sigma; m/z = 1046.54),
Peptide Sequencing Standard (Sigma Cat. # P2046; m/z = 1657.84),
and specific HP1 peptides.
Site-directed mutagenesis and construction of the transgene
expression vectors—Site-directed
mutagenesis was performed using the Transformer™ site-directed
mutagenesis kit (Clontech)
according to the manufacturers instructions. Site directed
mutagenesis was performed directly on
a pYC1.8-containing HP1 cDNA under the Hsp70 heat shock promoter
(34).
Genetic assays of phosphorylation site mutations—To measure the
ability of the different kinase
target mutations to affect heterochromatic position-effect
silencing, the following crosses were
performed: In(1)wm4/ In(1)wm4; Su(var)2-101/InCyRoi X v/Y;
transgene / Sco ; ry506 (when the
transgene is on the second chromosome) or In(1)wm4/ In(1)wm4;
Su(var)2-101/InCyRoi X v/Y;
transgene ry506 / Sb ry506(when the transgene is on the third
chromosome), where “transgene”
by guest on A pril 15, 2019
http://w w
w .jbc.org/
D ow
nloaded from
refers to either wild-type or mutant HP1 cDNA transgene constructs.
Progeny from each cross
were heat shocked twice daily at 37°C for 45 min throughout
development. Heat shocks were
spaced at least eight hours apart. Sons were collected, aged for
three or more days, and red eye
pigment was extracted and measured spectrophotometrically according
to the method of
Ephrussi and Herold (35). Pigment values are expressed as percent
of wild-type (Canton S) red
eye pigment each measurement was made using a minimum of 30 fly
heads.
RESULTS
HP1 is multiply phosphorylated when expressed from recombinant
baculovirus—Most of HP1
phosphorylation occurs at serines and threonines (27). Inspection
of the amino acid sequence of
HP1 reveals consensus target sites for several different protein
kinases (Fig. 1). We previously
showed that the N- and C-terminal casein kinase II (CKII) consensus
sites are phosphorylated in
vitro by an embryo nuclear extract CKII activity, suggesting that
these sites are used in vivo.
However, the CKII sites cannot explain the 7-8 distinct HP1
isoforms previously observed in
whole tissue extracts (27). To identify sites of HP1
phosphorylation, we expressed HP1 in Sf21
lepidopteran (Spodoptera frugiperda; the fall armyworm) cells using
recombinant baculovirus.
We reasoned that since HP1 is highly conserved, and since
lepidoptera are insects, these cells
would likely phosphorylate HP1 at the same sites as for HP1
expressed in Drosophila. Fig. 2
shows 2D gel analysis of total cellular protein from Sf21 cells
infected with recombinant
baculovirus expressing HP1. At least seven HP1 isoforms are
visible, the most basic of which
represents unphosphorylated HP1. We refer to the
baculovirus-expressed recombinant HP1 as
"SfHP1", and to the bacterially-expressed recombinant HP1 as
"rHP1." Previous work (32)
by guest on A pril 15, 2019
http://w w
w .jbc.org/
D ow
nloaded from
suggested that rHP1 is unphosphorylated, so rHP1 was used as a
reference polypeptide with
which SfHP1 was compared.
After purifying Sf HP1 from infected cells (see Methods), we used
matrix-assisted laser-
desorbtion/ionization time-of-flight (MALDI-TOF) mass spectroscopy
to examine the
postranslational modifications in SfHP1. A single major mass is
present in the rHP1 preparation
(Fig. 3A) corresponding to the expected mass of HP1 minus the
N-terminal methionine,
confirming that rHP1 is not posttranslationally modified beyond
N-terminal processing. In
contrast, the SfHP1 is distributed over multiple masses (Fig. 3B),
many separated by the mass of
one phosphate (80) and all major masses larger than the mass of
HP1. After phosphatase
treatment, the SfHP1 mass profile collapses into a single major
peak whose mass is equivalent to
that of HP1 minus the N-terminal methionine (Fig. 3C). Thus, SfHP1,
like the endogenous HP1
in Drosophila, is multiply phosphorylated. This analysis also shows
that there are no significant
posttranslational modifications in SfHP1 besides phosphorylation
and N-terminal processing.
Mapping sites of phosphorylation in HP1 using MALDI-TOF—To
determine whether consensus
kinase sites in HP1 are phosphorylated in vivo, we looked for
evidence that these motifs are
phosphorylated in SfHP1. We digested purified SfHP1 with different
endopeptidases and
subjected the peptides to MALDI-TOF mass analysis to identify
phosphopeptides (35).
Phosphopeptides were identified that contained each of the
consensus CKII sites (Figs. 4A and
4B). We previously showed that these sites are phosphorylated in
bHP1 by an embryo nuclear
extract in vitro; these results strongly suggest that the CKII
consensus sites are significantly
by guest on A pril 15, 2019
http://w w
w .jbc.org/
D ow
nloaded from
phosphorylated in vivo. Interestingly, a Lys C peptide containing
the N-terminal CKII site was
found to be doubly phosphorylated (Fig. 4A). This peptide also
contains a consensus protein
tyrosine kinase (PTK) motif. Platero et al. (34) showed that the
conservative substitution of
phenylalanine for tyrosine in this PTK motif resulted in loss of
silencing activity of the mutant
protein. The detection of a doubly-phosphorylated peptide
containing both a CKII and PTK
motif suggests that the consensus PTK site is used in vivo.
Unexpectedly, we found a LysC peptide whose mass corresponds to
that of a singly
phosphorylated internal peptide of HP1 without a consensus kinase
motif. While this study was
in progress, Koike et al. (30) reported that the human HP1-family
protein HP1Hsγ is a target for
the Pim-1 kinase proto-oncogene. Multiple sites of Pim-1
phosphorylation occur in HP1Hsγ, at
and dowstream of the sequence motif KRKS in the hinge region. Fig.
4C shows that a peptide
containing the single KRKS motif, which also occurs in the hinge
domain of Drosophila HP1, is
singly phosphorylated.
We found no consistent evidence for phosphorylation at either of
the two PKA/CaCK II
consensus sequences, or at the PKC consensus sequence motif.
Phosphorylation does not affect HP1 secondary structure or
dimerization in vitro—To test
whether phosphorylation causes significant changes in HP1 structure
in solution, circular
dichroism spectra were obtained using purified rHP1
(unphosphorylated) and SfHP1
by guest on A pril 15, 2019
http://w w
w .jbc.org/
D ow
nloaded from
phosphorylation does not significantly affect HP1 secondary
structure.
The HP1 C-terminal chromo domain can dimerize in vitro (16), which
could account for self-
association of rHP1 in solution (17). To test whether
phosphorylation can affect HP1 self-
association, we exposed solutions of purified rHP1 and SfHP1 to the
bifunctional crosslinking
agent dissuccinimidyl suberate, then separated proteins by SDS-PAGE
and immunolocalized
HP1 by western blot. As shown in Fig. 5B (compare lanes 2 and 4),
both SfHP1 and rHP1
preparations are crosslinkable as dimers to similar extents,
indicating that phosphorylation has no
significant effect on the efficiency of HP1 self-association.
Phosphorylation inhibits HP1 binding to DNA—We showed previously
that rHP1 binds to DNA
in vitro (17). To test whether phosphorylation affects DNA binding
activity of HP1, we
compared rHP1 and SfHP1 binding to a 146 bp DNA fragment in vitro.
As shown in Fig. 6A,
only rHP1 detectably binds DNA. To test whether the SfHP1 protein
preparation contains an
inhibitor of DNA binding, equal amounts of each protein were mixed
and challenged to bind
DNA; the mixture retards DNA mobility somewhat more than rHP1
alone, suggesting that
SfHP1 contributes to a band shift, but only in the presence of
unphosphorylated HP1. A likely
interpretation of this is that SfHP1 can form heterotypic complexes
with rHP1, but does not
contribute directly to DNA binding.
Surprisingly, phosphatase treatment of SfHP1 fails to restore DNA
binding activity (data not
shown). Judging from the MALDI mass analysis, phosphatase treatment
of SfHP1 yields a
by guest on A pril 15, 2019
http://w w
w .jbc.org/
D ow
nloaded from
spectrum nearly identical to that of unphosphorylated rHP1, with no
evidence of residual
modifications. This suggests that phosphorylation causes tertiary
conformational changes in HP1
structure that inhibit DNA binding, and that this structural
modification remains after
phosphatase treatment. Consistent with this possibility, we find
that dephosphorylated SfHP1
becomes insoluble.
To test the contribution of CKII phosphorylation to HP1 DNA binding
activity, mutant HP1
protein in which both target serines were substituted with either
alanine or glutamate (to mimic
phosphorylation) were expressed in E. coli and purified. As shown
in Fig. 6B, the double alanine
mutation band-shifts labeled DNA with similar efficiency to
wild-type HP1, but the double
glutamate mutation band-shifts DNA very poorly and with a distinct
mobility from the wild-type
protein. This suggests that CKII phosphorylation of HP1 contributes
significantly to the loss of
DNA binding in phosphorylated HP1 protein.
Mutations in HP1 phosphorylation sites abolish or antagonize
silencing activity—To test
whether HP1 phosphorylation is required for
heterochromatin-mediated gene silencing in vivo,
we replaced serines with either alanines (to block phosphorylation)
or glutamate (to mimic
constitutive phosphorylation) at sites containing serine/threonine
kinase consensus motifs. Ser15
and Ser202 fall within consensus motifs for CKII. Furthermore,
these sites were shown previously
to be phosphorylated in vitro by Drosophila embryo nuclear extract
(32). To test the role of
CKII consensus motifs in silencing, serine codons 15 and 202 were
replaced with alanine or
glutamate codons. Similarly, serines 89-91 and 102-104 are found
within consensus motifs for
cAMP-dependent protein kinase (PKA) and
calcium/calmodulin-dependent kinase II (CaCKII).
by guest on A pril 15, 2019
http://w w
w .jbc.org/
D ow
nloaded from
In these cases, three serines were simultaneously replaced with
three alanines or three
glutamates. Transgenic lines were established for these mutant HP1
proteins using P-element
mediated germ line transformation.
Mutant proteins were tested by expression under a Hsp70 heat shock
promoter in transgenic flies
carrying the white-variegating chromosome inversion In(1)wm4. The
dominant suppressor of
position effect variegation Su(var)2-1 was included in the
background to give a strong
background of pigmentation on which enhancement can readily be
detected. If the mutant protein
retains wild type silencing function, transgene expression will
enhance the silencing of the white
gene in the In(1)wm4 inversion, giving flies with reduced levels of
red eye pigment compared to
sibs that lack the transgene. Heat shock resulted in similarly
elevated levels of HP1 antigen by
Western blot in all transgenic lines, indicating that mutant
proteins were expressed at comparable
levels (data not shown).
Alanine and glutamate substitutions at either the N-terminal or
C-terminal CKII sites resulted in
proteins that had little or no ability to enhance position effect
silencing (Fig. 7). Surprisingly,
simultaneous substitution of alanines or glutamates at both target
sites results in a protein that
retains some silencing activity. However, the magnitude of the
silencing conferred by CKII
mutants (1.5-2 fold) was less than that seen for wild-type HP1
overexpression from the same
promoter (~3.5 fold), suggesting that the CKII mutant proteins are
not fully functional in this
assay. Similarly, a S15E,S202A double mutation also has reduced
silencing activity.
by guest on A pril 15, 2019
http://w w
w .jbc.org/
D ow
nloaded from
A triple alanine substitution at the upstream PKA/CaCK II consensus
motif (SSS89,90,91AAA)
results in loss of silencing activity, suggesting that these
serines are used in vivo (Fig. 7).
Strikingly, a triple alanine substitution at the downstream
PKA/CaCK II consensus motif
(SSS102,013,014AAA) results in protein that suppresses silencing in
two of three transgenic
lines (Fig. 7). Since this is the opposite of the normal activity
of HP1, this mutation results in an
antimorphic or “dominant negative” phenotype suggesting that the
mutant proteins antagonize
heterochromatin in vivo (37). Finally, a triple glutamate
substitution at the downstream
consensus also results in a protein defective in silencing. Thus,
both PKA/CaCK II motifs are
functionally important in HP1 silencing activity.
DISCUSSION
Our mutational studies (summarized in Table I) strongly implicate
multiple kinases in the
regulation of HP1 silencing activity in vivo. The fact that
silencing activity is reduced or lost
with mutations that block phosphorylation as well as with mutations
that mimic constitutive
phosphorylation suggests that both phosphorylated and
unphosphorylated isoforms are
functionally important and that HP1 phosphorylation is dynamic.
This is consistent with a
previous observation that HP1 phosphorylation continues to occur in
the absence of nascent
protein synthesis (27). We cannot exclude, however, that kinase
target site mutations may exert
their effects by affecting HP1 structure or HP1 protein-protein
interactions required for silencing.
by guest on A pril 15, 2019
http://w w
w .jbc.org/
D ow
nloaded from
Functional significance of HP1 phosphorylation—A recent study found
a correlation between
the extent of HP1 phosphorylation in embryos and salt
extractability (31). Extensively
phosphorylated HP1 was extractable at relatively low salt, while
high salt concentration was
required to solubilize hypophosphorylated HP1. Hypophosphorylated
HP1 was also found
associated with a high molecular weight (ca. 1 MDa) complex, while
extensively phosphorylated
HP1 was found in small (< 100 KDa) complexes. The functional
significance of differential salt
extractability and molecular complex formation is unknown, but
these observations suggest that
phosphorylation may regulate HP1 trafficking in the nucleus. We
reported previously that
mutations in CKII sites at either end of HP1 interfered with
efficient heterochromatin targeting in
vivo (32), consistent with this inference. The results reported
here showing reduced HP1
silencing activity for CKII site alanine and glutamate
substitutions further support the inference
that CKII phosphorylation is important to the mechanism of
HP1-mediated heterochromatin
formation.
Pim-1 kinase was found to associate with the human HP1-family
protein HP1Hsγ in a yeast two-
hybrid protein assay. Pim-1 is a proto-oncogene with multiple
targets (38,39). The functional
significance of Pim-1 phosphorylation is unknown, but Pim-1
expression is correlated with cell
proliferation in several systems. Since previous work indicated
that several serines are targeted
downstream of the Pim-1 kinase consensus target motif in HP1Hsγ
(30), we did not test mutations
in the two serines and single threonine within the Pim-1 consensus
peptide. The Drosophila
melanogaster genome contains three Pim-1 kinase homologs (CG3105,
CG11870, and CG8201).
No mutations are known for any of these genes, so it is not
possible to test the role of these
putative kinases in HP1 phosphorylation or heterochromatic
silencing.
by guest on A pril 15, 2019
http://w w
w .jbc.org/
D ow
nloaded from
Human HP1-family proteins associate with the silencing
transcriptional intermediary factors
TIF1α and TIF1β, and all three human HP1-like proteins are
substrates for the intrinsic kinase
activity of these factors (21). The physiological significance of
these associations, however, are
unknown, as are the target sites for phosphorylation in any of the
human HP1s. The Drosophila
melanogaster genome contains six putative genes with significant
homology to TIF1 family
proteins (bonus, GH10646, CG 14306, CG 1624, CG 3815, and CG 8419).
Of these, only bonus
has known mutant alleles (40). bonus is a late larval recessive
lethal required for peripheral
nervous system, midgut, fat body, and cuticle development (41). It
will be interesting to test
whether HP1 phosphorylation is affected in bonus mutant embryos or
larvae.
Unexpectedly, serine-to-alanine substitutions in the hinge region
connecting the chromo and
chromo shadow domains result in proteins that interfere with
heterochromatic silencing. This
"dominant negative" activity suggests that mutant proteins are
sequestering certain factors in
heterochromatin, but are unable to function in a competent
silencing complex. Thus,
phosphorylation in the hinge domain is also implicated in HP1
regulation in vivo, although we
were unable to detect significant amounts of phosphopeptides
containing either of the
PKA/CaCK II consensus motifs using MALDI analysis of
baculovirus-expressed HP1. DNA
binding activity has been localized to the hinge domain in the
human HP1-family protein HP1Hsα
(42), suggesting that phosphorylation in the hinge could act by
regulating HP1-DNA contacts.
We were unable to delimit DNA binding activity in rHP1 to a single
domain (17), suggesting
that multiple contacts mediating DNA binding are dispersed in
Drosophila HP1. Further studies
on HP1-DNA interaction--as well as interactions between HP1 and
histone and nonhistone
by guest on A pril 15, 2019
http://w w
w .jbc.org/
D ow
nloaded from
proteins--will be required in order to determine the mechanism of
phosphorylation-mediated
HP1 regulation.
Identification of sites of HP1 phosphorylation in HP1—We have
identified phosphopeptides
consistent with four distinct sites of HP1 phosphorylation.
Together with the unphosphorylated
HP1 isoform, this accounts for five of the seven isoforms visible
in the 2D gel of baculovirus-
expressed HP1. The mutational results suggest that both PKA/CaCKII
consensus kinase sites
may also be used, which could account for two more spots. There are
several possible reasons
why phosphopepetides containing these motifs were not detected in
our MALDI-TOF analysis:
(1) these sites may only be phosphorylated in a small fraction of
the total purified protein; (2)
phosphopeptides containing these sites may not desorb and/or ionize
efficiently during the
MALDI procedure; or (3) these sites may not be efficiently
phosphorylated in S. frugiperda cells.
Finally, our studies cannot rule out additional sites of
phosphorylation in vivo. The 2D
electrophoresis pattern only reveals the number of modifications in
a given isoform, not the sites
of modification, so in principle there could be more than six
potential phosphorylation sites.
The distributions of phosphorylated peptides and consensus motifs
implicates at least four
classes of protein kinases in the phosphorylation of HP1: CKII,
PKA/CaCKII, protein tyrosine
kinase and Pim-1 kinase. All of these kinases are known to have
multiple nuclear targets that
include transcriptional regulators. Thus, HP1 joins a substantial
fraction of nuclear factors as a
transcriptional regulator subject to posttranslational regulation
by phosphorylation.
by guest on A pril 15, 2019
http://w w
w .jbc.org/
D ow
nloaded from
Biochemical consequences of HP1 phosphorylation—We found that
phosphorylation of HP1 has
no detectable effect on HP1 secondary structure or dimerization,
but strongly interferes with HP1
binding to DNA. Serine-to-glutamate substitutions at the CKII
consensus target serines in HP1
have a severe effect on DNA binding of rHP1 in vitro, suggesting
that CKII phosphorylation
contributes significantly to the loss of SfHP1 DNA binding
activity. A simple mechanism by
which phosphorylation could alter DNA binding is by contributing to
electrostatic repulsion
between a phosphorylated domain and the DNA sugar-phosphate
backbone. Such a mechanism
would be expected to have little effect on the protein secondary
structure, which is what we
observe. Thus, phosphorylation can provide a mechanism to regulate
selectively HP1-DNA
interactions while preserving HP1-protein contacts.
Phosphorylation is known to control the activity of several
transcription factors (43,44). In some
cases, phosphorylation has been shown to regulate DNA binding
activity: for example,
phosphorylation of the POU transcription factor GHF-1 inhibits DNA
binding activity (46), and
phosphorylation of the zinc finger transcription factor SP1 by
casein kinase II reduces its DNA
binding activity (45). Phosphorylation of the architectural
transcription factor HMG-I reduces its
binding to DNA and nucleosomes in vitro (47). Hyperphosphorylation
of the yeast DNA-
damage-responsive transcription factor Crt1 inhibits its ability to
bind DNA (48). Calcium-
dependent phosphorylation inhibits DNA binding by the Ets-1
transcription factor 50-fold by
stabilizing an inhibitory secondary structure in the Ets-1 protein
(49). We found that
phosphorylated HP1 lacks detectable DNA binding activity in vitro,
suggesting that
phosphorylation could regulate HP1 in vivo by modulating its
ability to bind chromatin. In
addition, phosphorylation may regulate interactions between HP1 and
other heterochromatin-
by guest on A pril 15, 2019
http://w w
w .jbc.org/
D ow
nloaded from
phosphorylation in modulating such associations should be
tested.
Acknowledgements—We thank Dr. S.C.R. Elgin for HP1 antibody, Dr.
J.C. Lee for providing the
circular dichroism measurements, Dr. Y.-H. Chang for helpful
insights into MALDI mass
spectroscopy and its interpretation, Drs. A. Waheed and D. Dorsett
for critical reading of the
manuscript, and Dr. A. Waheed for much helpful discussion on
methodology and interpretation,
and for encouragement. This work was supported by NIH grant R55
GM57005 to JCE.
by guest on A pril 15, 2019
http://w w
w .jbc.org/
D ow
nloaded from
1. James, T.C., and Elgin, S.C.R. (1986) Mol. Cell. Biol. 6,
3862-3872
2. James, T.C., Eissenberg, J.C., Craig, C., Dietrich, V., Hobson,
A., and Elgin, S.C.R. (1989)
Eur. J. Cell Biol. 50, 170-180
3. Wustmann, G., Szidonya, J., Taubert, H., and Reuter G. (1989)
Mol. Gen. Genet. 217, 520-
527
4. Eissenberg, J.C., James, T.C., Foster-Hartnett, D.M., Hartnett,
T., Ngan, V., and Elgin, S.C.R.
(1990) Proc. Natl. Acad. Sci. USA 87, 9923-9927
5. Eissenberg, J.C., Morris, G.D., Reuter, G., and Hartnett, T.
(1992) Genetics 131, 345-352
6. Lu, B.Y., Emtage, P.C.R., Duyf, B.J., Hilliker, A.J., and
Eissenberg, J.C. (2000) Genetics 155,
699-708
7. Eissenberg, J.C., and Hartnett, T. (1993) Mol. Gen. Genet. 240,
333-338
8. Fanti, L., Giovinazzo, G., Berloco, M., and Pimpinelli, S.
(1998) Mol. Cell 2, 527-538
9. Eissenberg, J.C., and Elgin, S.C.R. (2000) Curr. Op. Genet.
Devel. 10, 204-210
by guest on A pril 15, 2019
http://w w
w .jbc.org/
D ow
nloaded from
10. Lorentz A., Ostermann, K., Fleck, O., and Schmidt, H. (1994)
Gene 143, 139-143
11. Festenstein, R., Sharghi-Namini, S., Fox, M., Roderick, K.,
Tolaini, M., Norton, T., Saveliev,
A., Kioussis, D., and Singh, P. (1999) Nature Genet. 23,
457-461
12. Ball, L.J., Murzina, N.V., Broadhurst, R.W., Raine, A.R.C.,
Archer, S.J., Stott, F.J., Murzina,
A.G., Singh, P.B., Domaille, P.F., and Laue, E.D. (1997) EMBO J.
16, 2473-2481
13. Brasher, S.V., Smith, B.O., Fogh, R. H., Nietispach, D., Thiru,
A., Nielsen, P.R.,
Broadhurst, R.W., Ball, L.J., Murzina, N.V., and Laue, E.D. (2000)
EMBO J. 19, 1587-
1597
14. Edmondson, S.P., Qiu, L. and Shriver, J.W. (1995) Biochemistry
34, 13289-13304
15. Robinson, H., Gao, Y.-G., McCrary, B.S., Edmondson, S. P.,
Shriver, F.W., and Wang, A.
H.-J. (1998) Nature 392, 202-205
16. Smothers, J.F., and Henikoff, S. (2000) Curr. Biol. 10,
27-30
17. Zhao, T., Heyduk, T., Allis, C.D., and Eissenberg, J.C. (2000)
J. Biol. Chem. 275, 28332-
28338
http://w w
w .jbc.org/
D ow
nloaded from
18. Le Douarin, B., Nielsen, A.L., Garnier, J.M., Ichinose, H.,
Jeanmougin, F., Losson, R., and
Chambon, P. (1996) EMBO J. 15, 6701-6715
19. Cléard, F., Delattre, M., and Spierer, P. (1997) EMBO J. 16,
5280-5288
20. Ryan, R.F., Schultz, D.C., Ayyanathan, K., Singh, P.B.,
Friedman, J.R., Fredericks, W.J., and
Rauscher, F.J., III (1999) Mol. Cell. Biol. 19, 4366-4378
21. Nielsen, A.L., Ortiz, J.A., You, J., Oulad-Abdelghani, M.,
Khechumian, R., Gansmuller, A.,
Chambon, P., and Losson R. (1999) EMBO J. 18, 6385-6395
22. Aagaard, L., Laible, G., Selenko, P., Schmid, M., Dorn, R.,
Schotta, G., Kuhfittig, S., Wolf,
A., Lebersorger, A., Singh, P.B., Reuter, G., and Jenuwein T.
(1999) EMBO J. 18, 1923-
1938
23. Ye, Q., and Worman, H.J. (1996) J. Biol. Chem. 271,
14653-14656
24. Ye, Q., Callebaut, I., Pezhman, A., Courvalin, J.C., and
Worman, H.J. (1997) J. Biol. Chem.
272, 14983-14989
25. Pak, D.T.S., Pflumm, M., Chesnodov, I., Huang, D.W., Kellum,
R., Marr, J., Romanowski,
P., and Botchan, M.R. (1997) Cell 91, 311-323
by guest on A pril 15, 2019
http://w w
w .jbc.org/
D ow
nloaded from
26. Murzina, N., Verreault, A., Laue, E., and Stillman, B. (1999)
Mol Cell 4, 529-540
27. Eissenberg, J.C., Ge, Y.-W., and Hartnett, T. (1994) J. Biol.
Chem. 269, 21315-21321
28. Huang, H., J.F. Smothers, E.A. Wiley, and C. D. Allis (1999)
Mol. Cell. Biol. 19, 3624-3634
29. Minc, E., Allory, Y., Courvalin, J.-C., Worman, H.J., and
Buendia, B. (1999) Chromosoma
108, 220-234
30. Koike, N., Maita, H., Taira, T., Ariga, H., and Iguchi-Ariga,
S.M.M. (2000) FEBS Letts.
467, 17-21
31. Huang, D.W., Fanti, L., Pak, D.T., Botchan, M.R., Pimpinelli,
S., and Kellum, R. (1998a) J.
Cell Biol. 142, 307-318
32. Zhao, T., and Eissenberg, J.C. (1999) J. Biol. Chem. 274,
15095-15100
33. Harlow, E., and Lane, D. (1988) Antibodies, A Laboratory
Manual, p. 505, Cold Spring
Harbor Lab Press, Cold Spring Harbor, NY
34. Platero, J.S., Hartnett, T., and Eissenberg, J.C. (1995) EMBO
J. 14, 3977-3986
by guest on A pril 15, 2019
http://w w
w .jbc.org/
D ow
nloaded from
35. Ephrussi, B., and Herold, J.L. (1944) Genetics 29,
148-175
36. Liao, P.-C., Leykam, J, Andrews, P.D., Gage, D.A., and Allison,
J. (1994) Analyt. Biochem.
219, 9020
37. Herskowitz, I. (1987) Nature 329, 219-222
38. Leverson, J.D., Doskinen, P.F., Orricol, F.C., Raino, E.-M.,
Jalkanen, K.F., Dash, A.B.,
Eisenman, R.N., and Ness, S.A. (1998) Mol. Cell 2, 417-425
39. Mochizuki, T., Kitanaka, C., Noguchi, K., Muramatsu, T., Asai,
A., and Kuchino, Y. (1999)
J. Biol. Chem. 274, 18659-18666
40. Salzberg, A., Prokopenko, S.N., He, Y., Tsai, P., Pal, M.,
Maroy, P., Glover, D.M., Deak, P.,
and Bellen, H.J. (1997) Genetics 147,1723-1741
41. Beckstead, R., Prokopenko, S., Losson, R., Chambon, P., and
Bellen, H. (1999)
Ann. Dros. Res. Conf. 40, 408B
42. Sugimoto, K., Yamada, T., Muro, Y., and Himeno, M. (1996) J.
Biochem. 120, 153-159
43. Hunter, T., and Karin, M. (1992) Cell 70, 375-387
by guest on A pril 15, 2019
http://w w
w .jbc.org/
D ow
nloaded from
44. Meek, D.W., and Street, A.J. (1992) Biochem. J. 287, 1-15
45. Caelles, C., Hennemann, H., and Karin, M. (1995) Mol. Cell.
Biol. 15, 6694-6701
46. Armstrong, S.A., Barry, D.A., Leggett, R.W., and Mueller, C.R.
(1997) J. Biol. Chem. 272,
13489-13495
47. Banks, G.C., Li, Y., and Reeves, R. (2000) Biochemistry 39,
8333-8346
48. Huang, M., Z. Zhou, and S.J. Elledge (1998b) Cell 94,
595-605
49. Cowley D. O., and Graves, B. J. (2000) Genes Devel.
14,366-376
by guest on A pril 15, 2019
http://w w
w .jbc.org/
D ow
nloaded from
Fig. 1. Consensus kinase target sites in HP1. The consensus target
sites for serine/threonine
kinases and protein tyrosine kinase are highlighted over a bar
representing Drosophila HP1.
Relative positions of the chromo domain (striped bar) and chromo
shadow domain (stippled bar)
motifs are indicated.
Fig. 2. 2-D gel analysis of recombinant baculovirus-expressed HP1.
Whole cell proteins were
extracted, fractionated by 2-D gel electrophoresis, and stained
with Coomassie blue. Asterisks
are placed over each HP1 isoform. (top) Total cell lysate. (bottom)
Unphosphorylated bacterially
expressed HP1 (ca. 1 µg) was added to the lysate as a mobility
standard (arrow), demonstrating
that baculovirus-expressed HP1 isoforms are more negatively
charged. Identities of the HP1
spots were independently confirmed by Western blot using anti-HP1
serum.
Fig. 3. MALDI-TOF mass analysis of recombinant HP1. (left) rHP1 is
unphosphorylated as
judged by 2-D electrophoresis (32). The mass of 23593.5 coincides
with the mass of HP1 minus
the N-terminal methionine (23594.8). The asterisk denotes a cluster
of peaks centered at 23818,
corresponding to the expected mass of HP1 minus the N-terminal
methionine plus a single
molecule of matrix adduct. (center) SfHP1 is extensively modified.
Arrow labeled “0” indicates
the mass position for unphosphorylated HP1 minus the N-terminal
methionine. Numbered
arrows indicate the expected positions for mono-, di-, tri-,
tetra-, penta-, and hexaphosphorylated
HP1 masses. (right) SfHP1 after treatment with phosphatase. Again,
the major peak at 23595.0
by guest on A pril 15, 2019
http://w w
w .jbc.org/
D ow
nloaded from
corresponds to unphosphorylated HP1 minus the N-terminal methionine
and the asterisk denotes
the position of the sinapinic acid adduct of this protein.
Fig. 4. MALDI identification of phosphopeptides in
baculovirus-expressed HP1. (A) An N-
terminal LysC peptide containing CKII and PTK consensus sites is
phosphorylated. Peak labeled
“a” has a mass of 2781, and corresponds to the peptide R[126-151]K.
(B) C-terminal peptides
containing a CKII site are phosphorylated (left) tryptic peptide
Peak labeled “a” has a mass of
1223 and corresponds to the peptide M[194-202]R. (right) GluC
peptide Peak labeled “b” has a
mass of 1346, and corresponds to the peptide Y[41-50]E. (C) linker
domain peptide containing
PIM-1 kinase target sites is phosphorylated. LysC peptide. Peak
labeled “a” has a mass of 1497
and corresponds to the peptide E[101-115]K ; peak labeled “b” has a
mass of 1391; its identity
is unknown.
Fig. 5. Phosphorylation does not affect HP1 secondary structure or
self-association. (A)Circular
dichroism was determined for rHP1 (dashed line) and SfHP1 (solid
line). Each line represents
the average of five separate measurements. (B) Purified recombinant
HP1 expressed in bacteria
(lanes 1and 2) or in Sf21 cells (lanes 3 and 4) was crosslinked in
solution. Crosslinked samples
shown in lanes 2 and 4. Proteins were then resolved by 10% SDS-PAGE
and subjected to
Western blot analysis using an anti-HP1 serum. Lane M shows the
relative mobilities of protein
standards whose masses are given on the left of the panel.
by guest on A pril 15, 2019
http://w w
w .jbc.org/
D ow
nloaded from
Fig. 6. Phosphorylation inhibits HP1 binding to DNA. (A) 10 µM
bacterially-expressed (lanes 1
and 4) or baculovirus expressed (lanes 3 and 4) was mixed with 10
nM Cy5-labeled 146 bp
DNA, then electrophoresed in a 8% native polyacrylamide gel. Note
that the baculovirus-
expressed protein alone does not shift the DNA, but enhances the
shift caused by bacterially
expressed HP1 (compare lanes 2 and 4). (B) 10 µM wild-type HP1, HP1
(SS15,202 AA) or HP1
(SS 15,202 EE) was mixed with 10 nM Cy5-labeled 146 bp DNA, and
electrophoresed in a 8%
native polyacrylamide gel.
Fig. 7. Mutations in HP1 phosphorylation sites reduce or abolish
silencing activity. Males
hemizygous for a transgene expressing wild-type or mutant HP1 were
crossed to In(1)wm4/
In(1)wm4 ; Su(var)2-101/InCyRoi females. Vials were heat shocked
twice daily throughout
development to express the transgenic HP1. Red eye pigment was
extracted from sons with and
without the transgene. A minimum of 30 flies was used for each
genotype, and typical standard
deviations were 10% (never more than 20%). For each cross, a ratio
of transgene-bearing to
control siblings was calculated. This ratio is log-transformed for
graphical presentation.
by guest on A pril 15, 2019
http://w w
w .jbc.org/
D ow
nloaded from
Table I. Summary of consensus kinase target site data for HP1
Consensus site
HP1 isoform Silencing activity1 Corresponding phosphopeptide
detected
Wild type +++ S15DAE S15A
yes
RPS89S90S91 SSS89,90,91AAA no enhancement no
RAS102S103S104 SSS102,103,104AAA SSS102,103,104EEE
1scoring system: +, enhanced silencing; 0, no effect on silencing;
-, reduced silencing (dominant negative activity)
2from Ref. 34.
http://w w
w .jbc.org/
D ow
nloaded from
kinase C proteinkinase II
Fig. 1
http://w w
w .jbc.org/
D ow
nloaded from
http://w w
w .jbc.org/
D ow
nloaded from
23593.5 23595.0
Fig. 3
http://w w
w .jbc.org/
D ow
nloaded from
http://w w
w .jbc.org/
D ow
nloaded from
http://w w
w .jbc.org/
D ow
nloaded from
http://w w
w .jbc.org/
D ow
nloaded from
http://w w
w .jbc.org/
D ow
nloaded from
http://w w
w .jbc.org/
D ow
nloaded from
http://w w
w .jbc.org/
D ow
nloaded from
Phosphorylation Site Mutations in Heterochromatin Protein 1 (HP1)
Reduce or
published online December 19, 2000J. Biol. Chem.
10.1074/jbc.M010098200Access the most updated version of
this article at doi:
Alerts:
When this article is cited•
to choose from all of JBC's e-mail alertsClick here
by guest on A pril 15, 2019
http://w w
w .jbc.org/
D ow
nloaded from